1. Pink Sheet

As Calls For Patent Sharing To Fight Pandemic Intensify, Manufacturing May Be Bigger Issue

 
• By Brenda Sandburg

Scientists and lawyers ask companies to temporarily license their IP for free, as others advocate compulsory licenses; real issue may be the ability to make a COVID-19 treatment or vaccine widely available.

Patent Health Care Pharmaceuticals Innovation concept.
Groups want biopharma companies to share their intellectual property for COVID-19 battle

Organizations, academicians and individuals continue to press companies to share their intellectual property for use in the battle against COVID-19. The call has gained traction, as drug and vaccine makers form collaborations and share their libraries of compounds. But a bigger issue may arise in assuring that products are widely available once they are approved.

Most recently, an international coalition of scientists and lawyers asked patent holders to commit to making their intellectual property available...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.